Role of induction therapy in low immunological risk-kidney transplant recipients: A mate-kidney analysis

2019 ◽  
pp. e13442 ◽  
Author(s):  
Kalathil K. Sureshkumar ◽  
Vinaikumar Katragadda ◽  
Bhavna Chopra ◽  
Marcelo Sampaio
Keyword(s):  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Immunosuppressive Management of Pediatric Kidney Transplant Recipients

2020 ◽  
Vol 26 (28) ◽  
pp. 3451-3459
Author(s):  
Tomáš Seeman
Keyword(s):  
Immunosuppressive Therapy ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Graft Loss ◽  
Calcineurin Inhibitors ◽  
Mtor Inhibitors ◽  
Therapeutic Drug ◽  
High Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

: Kidney transplantation is a preferable treatment of children with end-stage kidney disease. All kidney transplant recipients, including pediatric need immunosuppressive medications to prevent rejection episodes and graft loss. : Induction therapy is used temporarily only immediately following transplantation while maintenance immunosuppressive drugs are started and given long-term. There is currently no consensus regarding the use of induction therapy in children; its use should be decided based on the immunological risk of the child. : The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. The mTOR-inhibitors (sirolimus, everolimus) are used rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors. The use of calcineurin inhibitors, mycophenolate, and mTOR-inhibitors should be followed by therapeutic drug monitoring. : Immunosuppressive therapy of acute rejection consists of high-dose steroids and/or anti-lymphocyte antibodies (T-cell mediated rejection) or plasma exchange, intravenous immunoglobulines and/or rituximab (antibodymediated rejection). : The future strategies for research are mainly precise characterisation of children needing induction therapy, more specific indications for mTOR-inhibitors and for the far future, the possibility to reach the immuno tolerance.

scholarly journals Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Aziza Ajlan ◽  
Hassan Aleid ◽  
Tariq Zulfiquar Ali ◽  
Hala Joharji ◽  
Khalid Almeshari ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
First Year ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Double Blind ◽  
Donor Specific Antibodies

Abstract Background Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated. Aims To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC protocol. Methods Prospective, randomized, double blind, non-inferiority, controlled clinical trial Expected outcomes 1. Primary outcomes: Biopsy-proven acute rejection within first year following transplant 2. Secondary outcomes: a. Patient and graft survival at 1 year b. eGFR at 6 months and at 12 months c. Emergence of de novo donor-specific antibodies (DSAs) Trial registration The study has been prospectively registered at clinicaltrials.gov (NTC: 04404127). Registered on 27 May 2020.

Survival with Induction Therapy for Simultaneous Heart-Kidney Transplant Recipients on Tacrolimus/Mycophenolate

2017 ◽  
Vol 36 (4) ◽  
pp. S300
Author(s):  
A.A. Amin ◽  
V.K. Ariyamuthu ◽  
M.A. Urey ◽  
F.G. Araj ◽  
M.H. Drazner ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Role of Maraviroc in minimizing the risk of graft rejection in HIV‐infected kidney transplant recipients

2020 ◽  
Vol 22 (4) ◽  
Author(s):  
Gaetano Alfano ◽  
Giovanni Guaraldi ◽  
Francesco Fontana ◽  
Erica Franceschini ◽  
Giovanni Dolci ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Graft Rejection ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Optimal Dose of Thymoglobulin for Induction Therapy in High Risk Kidney Transplant Recipients

2016 ◽  
Vol 30 (2) ◽  
pp. 82
Author(s):  
Yaerim Kim ◽  
Seong Sik Kang ◽  
Woo Yeong Park ◽  
Kyubok Jin ◽  
Sung Bae Park ◽  
...  
Keyword(s):  
High Risk ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Optimal Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals The role of the pharmacist in the management of kidney transplant recipients

2016 ◽  
Vol 32 (3) ◽  
pp. 192 ◽  
Author(s):  
JoshuaJ Wiegel ◽  
AliJ Olyaei
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals The role of precision banding of arteriovenous fistulas in successful kidney transplant recipients

2020 ◽  
Vol 71 (2) ◽  
pp. 719
Author(s):  
William C. Jennings ◽  
Peter R. Nelson
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Arteriovenous Fistulas

Role of the Early Association of a mTOR Inhibitor and Tacrolimus in BK Polyomavirus Infection in Kidney Transplant Recipients

2018 ◽  
Vol 102 ◽  
pp. S566
Author(s):  
Veronica Lopéz ◽  
Teresa Vazquez ◽  
Cristina Jironda ◽  
Mercedes Cabello ◽  
Juana Alonso ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Mtor Inhibitor ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Bk Polyomavirus

scholarly journals Pre-Transplant Donor-Specific T-Cell Alloreactivity Is Strongly Associated with Early Acute Cellular Rejection in Kidney Transplant Recipients Not Receiving T-Cell Depleting Induction Therapy

PLoS ONE ◽  
2015 ◽  
Vol 10 (2) ◽  
pp. e0117618 ◽  
Author(s):  
Elena Crespo ◽  
Marc Lucia ◽  
Josep M. Cruzado ◽  
Sergio Luque ◽  
Edoardo Melilli ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Acute Cellular Rejection ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cellular Rejection
Sign in / Sign up

Export Citation Format

Share Document